Basal Cell Carcinoma with Disseminated Bone Metastization: An Unusual Outcome of the Most Common Malignancy
Basal cell carcinoma is the most common skin cancer, with a very low incidence of metastases, associated with high morbidity and mortality. The morpheaform clinical variant is uncommon, presenting an aggressive growth pattern. Early diagnosis and new targeted therapies for metastatic disease are important to improve survival rates. We present the case of a 29-year-old patient with morpheaform basal cell carcinoma in the right genian region. Due to local recurrences, he underwent surgery and adjuvant radiotherapy. For extensive metastatic bone involvement, the patient started vismodegib and, later, pembrolizumab, and also performed palliative radiotherapy. Despite several lines of systemic therapy, the disease progressed, and the patient died after 8 years of follow-up. This case shows how crucial it is to identify risk factors for metastatic basal cell carcinoma and highlights the need to improve target therapies and tailor them to the patient’s biological profile.
Freitas PP, Senna CG, Tabai M, Chone CT, Altemani A. Metastatic basal cell carcinoma: a rare manifestation of a common disease. Case Rep Med. 2017:1-4. doi: 10.1155/2017/8929745.
Nguyen-Nielsen M, Wang L, Pedersen L, Olesen AB, Mackey H, McCusker M, et al. The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010. Eur J Dermatol. 2015;25:463-468.
Snow SN, Sahl W, Lo JS, Mohs FE, Warner T, Dekkinga JA, et al. Metastatic basal cell carcinoma. Report of five cases. Cancer. 1994;73:328-35.
von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984;10:1043-60.
Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: A summary of published cases from 1981 through 2011. JAMA Dermatol. 2013;149:615-6.
Ascierto PA, Garbed C. Updates and new perspectives in nonmelanoma skin cancer from “Immunotherapy Bridge”. Immunotherapy. 2020;12:167-74. doi: 10.2217/imt-2020-0042.
Rodriguez C, Barriuso V, Chan LS. Extensive basal cell carcinoma with probable bone mestatases. Cutis. 2007;80:60-6.
McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014;50:774-83. doi: 10.1016/j.ejca.2013.12.013.
Spates ST, Mellette JR Jr, Fitzpatrick J. Metastatic basal cell carcinoma. Dermatol Surg. 2003;29:650-652.
Lau J, Guminski A, Gill A, Veivers D. Metastatic basal cell carcinoma: a review of six cases. Aust J of Otolaryngol. 2018;1:20.
Han A, Ratner D. What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? Cancer 2007;109:1053-1059.
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer. Version 1.2021. Fort Washington: NCCN; 2021.
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis K, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171-9. doi: 10.1056/NEJMoa1113713.
Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16:716-78. doi: 10.1016/S1470-2045(15)70100-2.
Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16:729-36. doi: 10.1016/S1470-2045(15)70198-1.
Jacobsen AA, Aldahan AS, Hughes OB, Shah VV, Strasswimmer J. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol. 2016;152:8. doi: 10.1001/jamadermatol.2016.0780.
Sekulic A, Migden MR, Basset-Seguin N, Garbed C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:332. doi: 10.1186/s12885-017-3286-5.
Cannon JGD, Russell JS, Kim J, Chang ALS. A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery. JAAD Case Rep. 2018;4:248-250.
Noubissi FK, Yedjou CG, Spiegelman VS, Tchounwou PB. Cross-Talk between Wnt and Hh Signaling Pathways in the Pathology of Basal Cell Carcinoma. Int J Environ Res Public Health. 2018;15:1442. doi: 10.3390/ijerph15071442.
Chang J, Zhu GA, Cheung C, Li S, Kim J, Chang AL. Association between programmed death ligand 1 expression in patients with basal cell carcinomas and the number of treatment modalities. JAMA Dermatol. 2017;153:285-90. doi: 10.1001/jamadermatol.2016.5062.
Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma-a review of the literature. Acta Oncol. 1996;35:677-82.
Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32:745-51. doi: 10.1200/JCO.2013.49.9525.
Copyright (c) 2021 Journal of the Portuguese Society of Dermatology and Venereology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).